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The expression of CD23 in cutaneous
non-lymphoid neoplasms
Background: Cluster designation 23 (CD23) is generally used as
a lymphoid marker. Its utility in cutaneous epithelial tumors has never
been studied. In our routine practice, we observed that CD23 reacted
strongly with eccrine and apocrine secretory coils.
Methods: Immunohistochemical staining of CD23 was performed in
a total of 131 cases of apocrine, eccrine, follicular and other cutaneous
non-lymphoid tumors.
Results: CD23 expression was detected in all benign apocrine
tumors and in half of benign eccrine tumors, particularly those derived
from secretory coils. CD23 staining was seen in 42% (8/19) of
microcystic adnexal carcinoma (MAC), while no staining was observed
in tumor cells of desmoplastic trichoepithelioma, morpheaform basal
cell carcinoma and syringoma. All mammary and extramammary
Paget’s disease were labeled with CD23. In comparison, pagetoid
Bowen’s disease, melanoma in situ and sebaceous carcinoma exhibited
negative staining. In addition, CD23 reacted diffusely with cutaneous
mucinous eccrine carcinoma in a manner similar to breast or colonic
adenocarcinoma.
Conclusion: CD23 appears to be a reliable immunohistochemical
marker of the eccrine/apocrine secretory coil and helpful in identifying
sweat gland tumors of such origin. It is of ancillary value in
differentiating MAC from its mimicker. CD23 is a useful addition to
the diagnostic immunohistochemical panels for Paget’s disease.
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Cluster designation 23 (CD23) is a type II trans-
membrane glycoprotein, which is the low-affinity
receptor for IgE. It is expressed by B cells, subsets of
monocytes/macrophages, T cells and eosinophils.1,2
Although CD23 is widely used as a lymphoid
marker3 in diagnosing chronic lymphocytic leuke-
mia, its expression has been demonstrated in normal
intestinal epithelium by several groups.4–6 Previously,
a few hematopoietic markers were found to be
expressed in some non-hematopoietic tumors, such as
CD56 in small-cell carcinoma,7 CD10 in renal cell
carcinoma8 and CD5 in thymic carcinoma, breast
and gastrointestinal adenocarcinoma.9–11 However,
at present, there have been no studies evaluating the
utility of CD23 in non-lymphoid tumors.
Cutaneous adnexal neoplasms comprise a hetero-
geneous group of tumors with eccrine, apocrine,
follicular and sebaceous differentiation. Some of
them share overlapping features and may present
diagnostic challenges. A number of immunohisto-
chemical markers12–16 have been used to determine
the histogenesis of sweat gland tumors in an attempt
to improve their identification and classification.
CD44 was shown to react with the non-luminal
surface of the normal eccrine secretory coil, but
failed to act as a useful marker for specific forms of
sweat gland differetiation.12 Staining with carcino-
embryonic antigen (CCEA) has been shown in
eccrine/apocrine ducts and in some eccrine secre-
tory coils.13 Later on, IKH-4 was reported to stain
eccrine secretory coil and tumors derived from it,
proving its usefulness in differentiating eccrine from
apocrine tumors.14 Recently, CD5 was detected in
the eccrine/apocrine secretory coil, some sweat
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gland tumors and Paget’s disease.16 Despite the
above effort, the histogenesis and classification of
sweat gland tumors remains a subject of discussion.
In our routine evaluation of cutaneous lymphoid
lesions, we observed that CD23 reacted strongly
with certain non-lymphoid tissue, such as eccrine
and apocrine secretory coils. We proposed that
CD23 could be used to study the histogenesis of
sweat gland tumors. In addition, we sought to
determine whether CD23 could help differentiate
microcystic adnexal carcinoma (MAC) from other
cutaneous infiltrating tumors and/or separate
Paget’s disease from other pagetoid lesions. These
aims prompted us to examine the CD23 expression
in a large group of skin tumors of different lineages,
as well as some non-cutaneous tumors.
Methods
After approval from the University of Michigan
Institutional Review Board for human subject
research, a search of the laboratory files of the
University of Michigan Pathology Department from
January 1995 to May 2006 was performed. From
this search, we identified 131 cutaneous tumors,
including 66 various benign cutaneous eccrine/
apocrine tumors, 19 MAC, 17 Paget’s disease
(mammary or extramammary), 2 mucinous eccrine
carcinoma and 27 other cutaneous neoplasms of
epithelial, follicular, sebaceous or melanocytic ori-
gin. In addition, nine cases of non-cutaneous
adenocarcinoma (breast or colon) were also included
in this study. All tumors examined are listed in
Table 1.
The original diagnoses were confirmed by
histologic review (L. M.). Using a mouse anti-human
monoclonal CD23 antibody at a 1:10 dilution (clone
BU38; The Binding Site, San Diego, CA, USA),
immunohistochemical staining was performed on
5-mm sections prepared from the formalin-fixed and
paraffin-embedded tissue blocks. All slides were
pretreated with protease for 16 min. Staining was
performed on a Ventana Benchmark XT system
(Ventana Medical Systems, Tucson, AZ, USA) using
the iVIEW diaminobenzidine reaction kit for
visualization.
The staining pattern and intensity of CD23 were
assessed on each stained slide. Any cytoplasmic stain-
ing was considered positive. The percentage of posi-
tive lesional cells was recorded as one of the four
categories: . 50%, . 10–50%, 1–10% and , 1%.
Cases classified as , 1% staining were those stained
with rare single cell, which were not tumor cells. The
intensity of staining was graded as strong or weak.
Results
In normal skin, CD23 labeled the luminal cells of
the eccrine/apocrine secretory coils (deep portion of
the glands) but not the outer myoepithelial cells
(Fig. 1A, B). The eccrine/apocrine intradermal and
intraepidermal ducts, follicular structures and seba-
ceous glands were not stained. Occasionally, the
dendritic processes of some dermal dendrocytes
demonstrated weak staining. In addition, CD23
staining was noted in salivary glands, normal breast
tissue (lobules and lactiferous ducts) as well as
colonic epithelium.
Table 1. CD23 immunostaining in cutaneous and non-cutaneous neoplasms
Percentage of CD23-positive cells Staining intensity
Tumor origin Tumor type n . 50 . 10–50 1–10 , 1 0 Strong Weak
Apocrine/eccrine Hidradenoma 12 1 2 6 0 3 5 4
Hidrocystoma 7 7 0 0 0 0 7 0
Syringocystadenoma papilliferum 5 5 0 0 0 0 5 0
Hidradenoma papilliferum 6 6 0 0 0 0 6 0
Poroma 9 0 0 2 0 7 2 0
Syringoma 6 0 0 0 0 6 0 0
Eccrine spiradenoma 8 0 4 4 0 0 4 4
Cylindroma 7 0 0 7 0 0 6 1
Chondroid syringoma 6 2 3 1 0 0 5 1
Microcystic adnexal carcinoma 19 3 1 4 0 11 5 3
Mucinous eccrine carcinoma 2 2 0 0 0 0 2 0
Epithelial Morpheaform basal cell carcinoma 6 0 0 0 1 5 1 0
Follicular Desmoplastic trichoepithelioma 7 0 0 0 3 4 3 0
Pagetoid Mammary Paget’s disease 8 8 0 0 0 0 8 0
Extramammary Paget’s disease 9 9 0 0 0 0 9 0
Pagetoid Bowen’s disease 6 0 0 0 0 6 0 0
Melanoma in situ 5 0 0 0 2 3 0 2
Sebaceous Sebaceous carcinoma 3 0 0 0 0 3 0 0
Non-cutaneous Breast ductal adenocarcinoma 4 4 0 0 0 0 4 0
Colonic adenocarcinoma 5 5 0 0 0 0 5 0
Cases classified as , 1% staining are those with rare single cell labeled. These cells do not appear to be the tumor cells.
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The results of staining are summarized in
Table 1. A comparison was made between apocrine
tumors and eccrine tumors (tumors which lack or
show very focal apocrine differentiation). Apocrine
tumors, such as hidradenoma papilliferum (6/6) and
syringocystadenoma papilliferum (5/5), demon-
strated diffuse (. 50%) and intense staining with
CD23 (Fig. 2A). Likewise, all seven cases of eccrine/
apocrine hidrocystomas and one apocrine hidrade-
noma displayed similar staining pattern (Fig. 2B).
A variable CD23 staining pattern was noted in
eccrine tumors. Most poromas (7/9) exhibited no
staining (Fig. 2C). In two poromas, very focal
staining was seen in an area of apocrine glandular
differentiation. Nearly all cases of hidradenomas
(11/12) demonstrated foci of luminal formation
without large area of apocrine differentiation (i.e.
apocrine decapitation, abundant eosinophilic cyto-
plasm) and were considered as eccrine hidrade-
nomas. Of note, four of these demonstrated a focal
apocrine component that was positive for CD23.
Two others (without obvious apocrine differentia-
tion) showed focal staining. Clear cell regions of
hidradenoma were uniformly negative. As for
eccrine spiradenoma (8/8), cylindroma (7/7) and
chondroid syringoma (6/6), CD23 focally labeled
Fig. 1. The expression of CD23 in normal
skin appendages. CD23 intensely labels the
luminal cells of eccrine (A) and apocrine
(B) secretory coils. However, the intrader-
mal and intraepidermal ductal units
(A) are negative (3 200).
Fig. 2. Diffuse and strong CD23 staining
is observed in hidradenoma papilliferum
(A) and hidrocystoma (B). Most eccrine
poroma (C) shows no staining. In contrast,
focal luminal staining is present in chon-
droid syringoma (D) (3 200).
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the inner epithelial cells or glandular structures,
sparing the peripheral lining cells (Fig. 2D). All
mucinous eccrine carcinoma (2/2) showed diffuse
and intense staining, a pattern similar to apocrine
tumors.
Among 19 MAC, CD23 reacted diffusely or
focally to eight cases (42%), selectively targeting the
glandular components (Fig. 3A). Areas of squamous
or follicular differentiation and syringoid MAC were
negative. The tumor cells of morpheaform basal cell
carcinoma, desmoplastic trichoepithelioma and
syringoma showed no staining (Fig. 3B). However,
in some cases (Table 1), very rare single CD23-
positive cells, some of which showed dendritic
morphology, were present within the tumor aggre-
gates or the overlying epidermis and interpreted to
not represent tumor cells. Similar cells were
occasionally seen in normal epidermis (data not
shown).
As illustrated in Fig. 4A, the tumor cells in both
mammary (8/8) and extramammary (9/9) Paget’s
disease were highlighted strongly and diffusely by
CD23, with membranous accentuation. In compa-
rison, none of the pagetoid Bowen’s disease (0/6) or
sebaceous carcinoma (0/3) exhibited any reactivity
(Fig. 4B). Of note, in two cases of melanoma in situ,
a few dendrites in the epidermis were weakly stained
by CD23.
As observed in cutaneous mucinous eccrine
carcinoma, mucinous carcinoma of breast (1/1) or
colonic (3/3) origin was also decorated by CD23 in a
similar pattern (Fig. 5A). Furthermore, diffuse and
strong staining was observed in non-mucinous breast
(3/3) and colon (2/2) adenocarcinoma (3/3) (Fig. 5B).
Discussion
In the current study, we characterized the staining
pattern of CD23 in normal eccrine and apocrine
glands and breast tissue. A distinction between the
ductal and secretary portion of the sweat glands can
be made by CD23 staining. In accordance with the
previous studies,4–6 we observed CD23 expression in
normal colonic epithelium.
Our data showed that CD23 is widely expressed
in a variety of sweat gland tumors. We suspect that
this expression may be dependent on the tumor type
(eccrine or apocrine) and differentiation (ductal or
secretory). As observed in the CD5 study,16 we found
that all apocrine tumors expressed CD23 diffusely
whereas only about half of the eccrine tumors
demonstrated focal staining. Apocrine tumors (tra-
ditionally shown to have apocrine decapitation and
ample amounts of eosinophilic cytoplasm) show
strong CD23 reactivity, mimicking the staining
pattern of normal apocrine secretory coils. Conven-
tionally, some eccrine tumors (i.e. eccrine spirade-
noma, cylindroma and chondroid syringoma) are
believed to be derived from the eccrine secretory coil
or the transitional region between duct and
secretory coil.17,18 This origin is reflected in the
staining pattern observed as tumors with focal lumi-
nal staining, a pattern analogous to normal eccrine
secretory coil. In contrast, those eccrine tumors that
possibly originate from ductal segments,19,20 such as
poroma and syringoma, exhibited no staining,
a pattern similar to that seen in the normal eccrine
duct. Of interest, mucinous eccrine carcinoma,
which is traditionally thought to be derived from
eccrine secretory coil,21,22 showed a diffuse and
strong staining pattern similar to that seen with
clear-cut apocrine tumors. This makes one specu-
late as to whether or not mucinous eccrine car-
cinoma is indeed of eccrine origin and awaits further
clarification.
Similarly, the origin of the tumor cells probably
contributed to the variable CD23 staining seen in
hidradenomas. We suspect that those with over-
lapping features of poroma may be derived from the
upper portion of the sweat gland and showed no
staining. Hidradenomas with extensive clear cell
regions were not labeled possibly because these cells
Fig. 3. (A) A proportion of microcystic
adnexal carcinoma shows focal strong
CD23 positivity in the glandular areas, while
morpheaform basal cell carcinoma shows
no reactivity for tumor cells (B) (3 200).
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could come from immature poral epithelium.
Tumors with apocrine features were focally positive,
indicating a possible origin from the deeper portion
of the sweat gland.
As MAC is a heterogeneous group of adnexal
neoplasm, a variable pattern of staining was
observed. As previously reported for CD5,16 CD23
also only labeled the glandular elements. The
presence of rare CD23-positive cells in some MAC
mimickers, such as desmoplastic trichoepithelioma
and basal cell carcinoma, is of great interest.
According to their morphology and distribution,
we suspect that these cells may represent entrapped
or pre-existing Merkel cells. Further studies to
confirm this hypothesis are necessary.
As expected, because of its derivation from
modified apocrine glands, CD23 consistently
reacted with the tumor cells of Paget’s diseases.
These results are compatible with the study by
Bogner et al.,16 in which CD5 labeled Paget’s
disease, but not other pagetoid lesions. In future, the
overall sensitivity and specificity of CD23 needs to
be compared with other well-known markers (i.e.
cytokeratin 723) for Paget’s disease. The nature and
significance of finding occasional staining for
epidermal dendrites in melanoma in situ are
unknown. It may be labeling the dendritic processes
of Langerhans cells, which have been previously
reported to express CD23 and therefore assist in
antigen presentation.24,25
Although CD23 cannot help to distinguish
primary cutaneous mucinous eccrine carcinoma
from metastatic mucinous carcinoma, the fact that
breast and colon adenocarcinoma reacted strongly
with CD23 is very interesting. A larger number of
cases are needed to confirm our finding. Further-
more, in analogy to CD5,10 it would be interesting
to investigate possible correlation between the CD23
expression level and the tumor grade of breast
carcinomas.
The molecular basis of CD23 expression in non-
lymphoid epithelial cells remains unclear. One
explanation is that CD23 may react with endoge-
nous IgE present in the glandular epithelium due to
its low binding affinity for IgE.1 Alternatively, it may
be recognizing an epitope shared by another
antigen, such as certain types of cytokeratins. Future
studies to determine the expression of other CD23
clones in sweat gland tumors may provide insight
into its role in the biology of these tumors.
In conclusion, we found that CD23 is preferen-
tially expressed in apocrine tumors and in a subset of
eccrine tumors derived from the eccrine secretory
coil. Its expression may help identify the histogenesis
Fig. 4. (A) CD23 is strongly expressed in
mammary Paget’s disease, but is negative
in pagetoid Bowen’s disease (B) (3 200).
Fig. 5. (A) Mucinous eccrine carcinoma
shows diffuse and intense positivity for
CD23. (B) Similar staining patterns are
detected in breast ductal adenocarcinoma
(3200).
CD23 expression in non-lymphoid neoplasms
697
of sweat gland tumors. CD23 may be of some value
in discriminating MAC from other cutaneous
infiltrating tumors. In addition, it may serve as
a useful adjunct to the diagnostic immunohisto-
chemical panels for mammary and extramammary
Paget’s disease.
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